• Journal of Preventive Medicine and Public Health
• /
• 제20권1호
• /
• pp.129-136
• /
• 1987

의대생들의 B형바이러스성 간염의 감염율을 조사하고 그 예방대책을 강구하기 위하여 경북의대 1, 2, 3학년 가운데 B형 간염 백신 예방접종을 받은 학생을 제외한 자원자 385명을 대상으로 HBsAg, anti-HBs, anti-HBc를 RIA방법으로 측정하여 B형간염 감염율을 조사하고 설문지로 수혈력, 침술력, 수술력을 조사하고 HBsAg양성인 사람은 16개월 후에 재검사하여 변화양상을 조사하였다. HBsAg양성율은 6.8%이었으며 연령에 대한 보정을 했을 때 남자가 7.2%로 여자의 4.9%보다 높았으며, anti-HBs양성율은 35.8% (남자 36.1%, 여자 37 9%), anti-HBc양성율은 45.5% (남자 46.5%, 여자 44.5%)이었다. 따라서 B형간염 감염율은 49.1%로서 역시 남자(50.3%)가 여자보다(46.5%) 높았다. 학년별 HBsAg양성율 및 HBV감염율의 차이는 연령구성의 차이에 기인된 것 이었으며 연령별 HBsAg양성율은 20세가 1.7%, 21세 6.6%, 22세 6.1%, 23세 12.2%, 24세 이상에서 6.4%로 23세에서 가장 높게 나타났다. HBV감염율은 20세에서 45.8%, 21세 41.5%, 22세 49.5%, 23세 55.4%, 24세이상에서 59.6%로 나타나 연령이 증가할수록 감염율은 증가하였다. 이와같은 연령별 차이는 통계적으로 유의한 것은 아니었으나 타 연구결과와 종합해 볼 때 연령별 차이가 있을 것으로 생각되므로 같은 연령의 다른 학교 및 다른 계층을 대상으로 조사해 보고 연령에 따른 차이가 생기는 이유를 규명한다면 이 연령층에서 B형간염의 주요전파 경로를 밝힐 수 있을 것으로 생각된다. HBsAg양성인 26명가운데 1명만이 B형간염을 않고 있는 환자로 밝혀졌고 이들은 16개월 후에 재경사한 결과 검사에 응한 24명 중 22명이 계속 HBsAg양성이고 2명은 음성으로 되고 anti-HBs가 양성으로 나타났다. 본 연구 결과로 보아 20세 이전에 약 반이 B형간염에 감염되었고 재학중에도 감염이 일어나고 있으므로 입학 즉시 감염여부를 확인하고 미감염자에 대해 예방접종을 실시하고 임상에 종사하기 시작할 때 추가접종하는 것이 이상적일 것으로 생각된다.

• 대한임상검사과학회지
• /
• 제36권1호
• /
• pp.13-18
• /
• 2004

This study was designed to establish working range for reoportable range in own laboratory in order to cover the upper and lower limits of the range in test method. We experimented ten times during 10 days for setting of reportable range with between run for method evaluation. It is generally assumed that the analytical method produces a linear response and that the test results between those upper and lower limits are then reportable. CLIA recommends that laboratories verify the reportable range of all moderate and high complexity tests. The Clinical Laboratory Improvement Amendments(CLIA) and Laboratory Accreditation Program of the Korean Society for Laboratory Medicine states reportable range is only required for "modified" moderately complex tests. Linearity requirements have been eliminated from the CLIA regulations and from others accreditation agencies, many inspectors continue to feel that linearity studies are a part of good lab practice and should be encouraged. It is important to assess the useful reportable range of a laboratory method, i.e., the lowest and highest test results that are reliable and can be reported. Manufacturers make claims for the reportable range of their methods by stating the upper and lower limits of the range. Instrument manufacturers state an operating range and a reportable range. The commercial linearity material can be used to verify this range, if it adequately covers the stated linear interval. CLIA requirements for quality control, must demonstrate that, prior to reporting patient test results, it can obtain the performance specifications for accuracy, precision, and reportable range of patient test results, comparable to those established by the manufacturer. If applicable, the laboratory must also verify the reportable range of patient test results. The reportable range of patient test results is the range of test result values over which the laboratory can establish or verify the accuracy of the instrument, kit or test system measurement response. We need to define the usable reportable range of the method so that the experiments can be properly planned and valid data can be collected. The reportable range is usually defined as the range where the analytical response of the method is linear with respect to the concentration of the analyte being measured. In conclusion, experimental results on reportable range using concentrated control sample and zero calibrators covering from highest to lowest range were salicylate $8.8{\mu}g/dL$, phenytoin $0.67{\mu}g/dL$, phenobarbital $1.53{\mu}g/dL$, primidone $0.16{\mu}g/dL$, theophylline $0.2{\mu}g/dL$, vancomycine $1.3{\mu}g/dL$, valproic acid $3.2{\mu}g/dL$, digitoxin 0.17ng/dL, carbamazepine $0.36{\mu}g/dL$ and acetaminophen $0.7{\mu}g/dL$ at minimum level and salicylate $969.9{\mu}g/dL$, phenytoin $38.1{\mu}g/dL$, phenobarbital $60.4{\mu}g/dL$, primidone $24.57{\mu}g/dL$, theophylline $39.2{\mu}g/dL$, vancomycine $83.65{\mu}g/dL$, valproic acid $147.96{\mu}g/dL$, digitoxin 5.04ng/dL, carbamazepine $19.76{\mu}g/dL$, acetaminophen $300.92{\mu}g/dL$ at maximum level.